Eribulin as First-Line Therapy for Metastatic HER2-Negative Breast Cancer

Clinical Pearls

Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the results of a recent breast cancer study.

• This study looked at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
• Overall response rate was 29%.
• Clinical benefit rate was 52%.
• Median PFS was 6.8 months.
• Responses were seen regardless of ER status.